Drugs / IMA950
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials · 1 met primary | ||||||
| Phase 1 | NCT02924038 | Apr 2017 → Dec 2022 | astrocytic tumor, oligoastrocytoma, oligodendroglioma | Nicholas Butowski | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01403285 | Aug 2011 → Apr 2014 | glioblastoma | Immatics Biotechnologies GmbH | Terminated | Met primary Stop: Enrollment |
| Phase 1 | NCT01222221 | Jul 2010 → Feb 2015 | central nervous system neoplasm | Cancer Research UK | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01920191 | Aug 2013 → Mar 2016 | glioma | University Hospital, Geneva | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03665545 Background | Oct 2018 → Dec 2023 | adult glioblastoma, brain glioblastoma | University Hospital, Geneva | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-04-23 | Immatics Biotechnologies GmbH | Results Promising results in phase 1 trial lead Immatics to continue work on vaccine (IMA950) for glioblastoma immatics.com ↗
Results showed that 90 per cent of patients responded to the vaccine, in comparison to the pre-defined goal of 60 per cent, exceeding expectations. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-04-23 | Immatics Biotechnologies GmbH | Promising results in phase 1 trial lead Immatics to continue work on vaccine (IMA950) for glioblastoma immatics.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMA950 | “Using antigens eluted from the surface of glioblastoma samples, we designed a phase I/II study to test safety and immunogenicity of the IMA950 multipeptide vaccine adjuvanted...” PMID 30753611 ↗ Jul 2019 |
| Action | Activate | “designed to activate TUMAP-specific T cells” NCT01403285 ↗ |
| Modality | Vaccine | “glioblastoma multiforme multipeptide vaccine IMA950” NCT01222221 ↗ |
| Route | Subcutaneous | “subcutaneously administered IMA950 peptides and poly-ICLC” NCT02924038 ↗ |